Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder

NCT01981811 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped The trial was terminated because it was determined that the usability of the MIND1 System in the intended population was necessary before conducting this trial.

Conditions

Bipolar 1 Disorder
Schizophrenia
Mental Disorder
Nervous System Diseases

Interventions

DRUG: Aripiprazole
DEVICE: Ingestible Event Marker (IEM)

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.